{"id":"NCT00366548","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","briefTitle":"Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants","officialTitle":"A Phase 3, Randomized, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Manufactured With and Without Polysorbate 80 in Healthy Infants Given in a 2-, 3-, 4-, and 12-Month Schedule With Routine Pediatric Vaccinations","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-11","primaryCompletion":"2008-06","completion":"2008-06","firstPosted":"2006-08-21","resultsPosted":"2012-08-15","lastUpdate":"2012-08-15"},"enrollment":500,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Vaccines, Pneumococcal"],"interventions":[{"type":"BIOLOGICAL","name":"13 valent pneumococcal conjugate vaccine with Polysorbate 80","otherNames":[]},{"type":"BIOLOGICAL","name":"13 valent pneumococcal conjugate vaccine without Polysorbate 80","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine manufactured with Polysorbate 80 compared to a 13-valent pneumococcal conjugate (13vPnC) manufactured without Polysorbate 80 when given concomitantly with routine paediatric vaccinations.","primaryOutcome":{"measure":"Percentage of Participants Achieving Antibody Level ≥0.35μg/mL in 13vPnC+P80 Group Relative to 13vPnC-80 Group After the Infant Series","timeFrame":"One month after 3-dose infant series (at 5 months of age)","effectByArm":[{"arm":"13vPnC + Polysorbate 80 After the Infant Series","deltaMin":93.3,"sd":null},{"arm":"13vPnC - Polysorbate 80 After the Infant Series","deltaMin":94.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"42 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":14,"countries":["Poland"]},"refs":{"pmids":["25126854"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":249},"commonTop":["Irritability","Increased sleep","Erythema (Any)","Erythema (Mild)","Tenderness (Any)"]}}